Top Markets
#1 PulseChain PulseChain +45.13%
#2 Glidr Glidr +11.05%
#3 Fake World Assets Fake World Assets +9.47%
#4 Meteora Meteora +7.99%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +6.90%
#6 eCash eCash +6.72%
#7 Qkacoin Qkacoin +6.49%
#8 OPENLOOT OPENLOOT +5.89%
#9 Velvet Velvet +5.57%
#10 Tornado Cash Tornado Cash +5.56%
Coin of the day
PulseChain PulseChain
Innstillinger
Språk
NORSK
Valuta
USD
Tema
AgeX Therapeutics, Inc. AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc.

AGE
Rangering i aksjer #28237
AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to... AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to pioneering and commercializing groundbreaking therapies that address human aging and degenerative conditions. The company's developmental pipeline features several promising cell-based therapeutic candidates: AGEX-BAT1: A cell therapy designed to manage various age-related metabolic disorders, including adult-onset Type II diabetes and obesity. AGEX-VASC1: A cell-based approach aimed at re-establishing vital vascular support in aged ischemic tissues, which could be relevant for conditions such as peripheral vascular disease and ischemic heart disease. Beyond cell therapies, AgeX is also exploring other modalities: Its primary drug candidate in the discovery phase is AGEX-iTR1547, a drug formulation focused on achieving scarless wound repair. For induced tissue regeneration, its leading biologic candidate is AGEX-iTR1550, which leverages gene delivery technology. Furthermore, AgeX maintains a research collaboration with the University of California at Irvine, jointly working to develop cellular therapies for various neurological disorders. Founded in 2017, AgeX Therapeutics, Inc. maintains its headquarters in Alameda, California.
Aksjekurs
$11.10
Sist synkronisert: 2024-03-26
Markedsverdi
$27.76M
Endring (1 dag)
-11.90%
Endring (1 år)
0.00%
Land
US
Handel AgeX Therapeutics, Inc. (AGE)

Kategori

Healthcare
P/E-forhold for AgeX Therapeutics, Inc. (AGE)
P/E-forhold per 2026 TTM: 0
Ifølge AgeX Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for AgeX Therapeutics, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.